Filing Details
- Accession Number:
- 0000937556-25-000084
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-05-14 17:32:56
- Reporting Period:
- 2025-05-12
- Filing Date:
- 2025-05-14
- Accepted Time:
- 2025-05-14 17:32:56
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 937556 | Masimo Corp | MASI | Electromedical & Electrotherapeutic Apparatus (3845) | 330368882 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1734507 | Bilal Muhsin | C/O Masimo Corporation 52 Discovery Irvine CA 92618 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-05-12 | 10,000 | $34.51 | 34,172 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-05-12 | 3,881 | $162.72 | 30,291 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-05-12 | 5,594 | $163.51 | 24,697 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-05-12 | 525 | $164.96 | 24,172 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (Right to Buy) | Disposition | 2025-05-12 | 10,000 | $34.51 | 10,000 | $34.51 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2016-05-13 | 2025-05-13 | No | 4 | M | Direct |
Footnotes
- The shares covered by this Form 4 were exercised and sold pursuant to a Rule 10b5-1 Sales Plan dated as of December 13, 2024, which is intended to comply with Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended.
- The price reported in Column 4 represents the weighted average purchase price per share. The actual sale prices ranged from a low of $162.16 per share to a high of $163.14 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- The price reported in Column 4 represents the weighted average purchase price per share. The actual sale prices ranged from a low of $163.19 per share to a high of $163.90 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- The price reported in Column 4 represents the weighted average purchase price per share. The actual sale prices ranged from a low of $164.56 per share to a high of $165.27 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- This option was granted on May 13, 2015 and was exercisable as the option vested. This option vested over a five year period, with 20% of the shares subject to the option vesting on each anniversary of the grant date.
Billionaire Hedge Funds
